Nektar Therapeutics (NASDAQ:NKTR) Receives $149.63 Consensus Price Target from Analysts

Posted by on Jun 28th, 2026

Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $149.6250.

NKTR has been the subject of a number of analyst reports. Wedbush decreased their target price on shares of Nektar Therapeutics from $95.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, May 11th. Citigroup increased their target price on shares of Nektar Therapeutics from $123.00 to $151.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. BTIG Research upped their price target on shares of Nektar Therapeutics from $151.00 to $178.00 and gave the company a “buy” rating in a research note on Monday, April 20th. HC Wainwright upped their price target on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research note on Monday, April 20th. Finally, TD Cowen started coverage on shares of Nektar Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating on the stock.

Get Our Latest Stock Analysis on Nektar Therapeutics

Insider Buying and Selling

In other news, insider Jonathan Zalevsky sold 5,538 shares of Nektar Therapeutics stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $60.71, for a total value of $336,211.98. Following the sale, the insider owned 15,437 shares in the company, valued at $937,180.27. This trade represents a 26.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard W. Robin sold 10,000 shares of Nektar Therapeutics stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer owned 65,045 shares in the company, valued at approximately $3,923,514.40. This trade represents a 13.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,181 shares of company stock worth $981,535 in the last 90 days. 2.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Nektar Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its holdings in Nektar Therapeutics by 93.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 210 shares in the last quarter. KBC Group NV purchased a new stake in shares of Nektar Therapeutics in the 1st quarter valued at approximately $52,000. State of Wyoming purchased a new stake in shares of Nektar Therapeutics in the 1st quarter valued at approximately $67,000. Quarry LP purchased a new stake in shares of Nektar Therapeutics in the 4th quarter valued at approximately $85,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in shares of Nektar Therapeutics in the 4th quarter valued at approximately $92,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

Nektar Therapeutics Stock Performance

NASDAQ:NKTR opened at $63.65 on Tuesday. The firm’s 50-day moving average is $71.53 and its 200-day moving average is $62.39. Nektar Therapeutics has a 52-week low of $21.02 and a 52-week high of $109.00. The company has a market cap of $2.15 billion, a price-to-earnings ratio of -7.56 and a beta of 1.13.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.58) by ($0.24). The company had revenue of $10.86 million for the quarter, compared to the consensus estimate of $10.69 million. Nektar Therapeutics had a negative return on equity of 85.40% and a negative net margin of 284.18%. Equities analysts predict that Nektar Therapeutics will post -9.45 EPS for the current year.

About Nektar Therapeutics

(Get Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.

Featured Stories

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.